Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials
Lifen Qiao,1,2,* Jin Wang,2,3,* Guoxian Long,2,4 Yueqiang Jiang1,5 1Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 2Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA; 3Department of Emergency, 4Department...
Main Authors: | Qiao L, Wang J, Long G, Jiang Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-02-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/sequential-treatment-of-tyrosine-kinase-inhibitor-and-platinum-based-d-peer-reviewed-article-OTT |
Similar Items
-
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
by: Holleman MS, et al.
Published: (2019-02-01) -
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014-01-01) -
Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
by: Shi X, et al.
Published: (2020-07-01) -
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
by: Svenja Wagener-Ryczek, et al.
Published: (2020-05-01) -
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
by: Eric Santoni-Rugiu, et al.
Published: (2019-07-01)